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The chromatin landscape of primary synovial sarcoma
organoids is linked to specific epigenetic mechanisms and
dependencies
Gaylor Boulay3,4,*, Luisa Cironi1,2,* , Sara P Garcia3,†, Shruthi Rengarajan3,†, Yu-Hang Xing3, Lukuo Lee3, Mary E Awad3,
Beverly Naigles3 , Sowmya Iyer3, Liliane C Broye1,2, Tugba Keskin1,2, Alexandra Cauderay1,3, Carlo Fusco1,2,
Igor Letovanec1, Ivan Chebib3, Petur Gunnalugur Nielsen3, Stéphane Tercier6 , Stéphane Cherix5 , Nguyen-Ngoc Tu7,
Gregory Cote8 , Edwin Choy8 , Paolo Provero9,10 , Mario L Suvà3,4, Miguel N Rivera3,4, Ivan Stamenkovic1,2 ,
Nicolò Riggi1,2
Synovial sarcoma (SyS) is an aggressive mesenchymal malig-
nancy invariably associated with the chromosomal transloca-
tion t(X:18; p11:q11), which results in the in-frame fusion of the
BAF complex gene SS18 to one of three SSX genes. Fusion of SS18
to SSX generates an aberrant transcriptional regulator, which, in
permissive cells, drives tumor development by initiating major
chromatin remodeling events that disrupt the balance between
BAF-mediated gene activation and polycomb-dependent re-
pression. Here, we developed SyS organoids and performed
genome-wide epigenomic profiling of these models and mes-
enchymal precursors to define SyS-specific chromatin remod-
eling mechanisms and dependencies. We show that SS18-SSX
induces broad BAF domains at its binding sites, which oppose
polycomb repressor complex (PRC) 2 activity, while facilitating
recruitment of a non-canonical (nc)PRC1 variant. Along with the
uncoupling of polycomb complexes, we observed H3K27me3
eviction, H2AK119ub deposition and the establishment of de
novo active regulatory elements that drive SyS identity. These
alterations are completely reversible upon SS18-SSX depletion
and are associated with vulnerability to USP7 loss, a core
member of ncPRC1.1. Using the power of primary tumor orga-
noids, our work helps define the mechanisms of epigenetic
dysregulation on which SyS cells are dependent.
DOI 10.26508/lsa.202000808 | Received 5 June 2020 | Revised 1 December
2020 | Accepted 10 December 2020 | Published online 23 December 2020
Introduction
Synovial sarcoma (SyS) is the second most common soft tissue
malignancy in the adolescent and young adult population, in which it
comprises 10–20% of all soft tissue sarcomas (Nielsen et al, 2015). Its
defining genetic feature is the chromosomal translocation t(X:18; p11:
q11), which generates fusions between the nearly entire coding
sequence of the SS18 gene and a portion of an SSX gene family
member (SSX1 and SSX2 being the two most commonly implicated
[Nielsen et al, 2015; Riggi et al, 2018]). As is often observed in pediatric
malignancies, SyS displays few genetic mutations other than the
chromosomal translocation itself, suggesting that SS18-SSX bears the
prime responsibility for SyS pathogenesis. Accordingly, a transgenic
mousemodel of SySwas generated by expressing human SS18-SSX in
an early Myf5+ murine myoblast population (Haldar et al, 2007).
Whereas this model pointed to Myf5+ myoblasts as a potential cell of
origin of SyS, experiments using conditional expression of SS18-SSX
produced tumors in atypical anatomic locations, suggesting that
other cell types may also be permissive for SS18-SSX–mediated
transformation. Consistent with this notion, mouse and human
mesenchymal stem cells (MSCs) have been shown to acquire a gene
expression profile that resembles that of primary human SyS upon
expression of SS18-SSX (Cironi et al, 2009, 2016).
The oncogenic properties of SS18-SSX have been linked to its
ability to interact with proteins that control epigenetic states (Thaete
1Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Faculty of Biology andMedicine, University of Lausanne, Lausanne, Switzerland 2Swiss Cancer Center Leman, Centre
Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland 3Department of Pathology and Center for Cancer Research,
Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA 4Broad Institute of Harvard and MIT, Cambridge, MA, USA 5Department of Orthopedics, Faculty
of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland 6Department of Woman-Mother Child, Centre Hospitalier Universitaire Vaudois, Faculty of
Biology andMedicine, University of Lausanne, Lausanne, Switzerland 7Department ofOncology, CentreHospitalier Universitaire Vaudois, Faculty of Biology andMedicine, University of
Lausanne, Lausanne, Switzerland 8Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA 9Center for Translational
Genomics and Bioinformatics, San Raffaele Scientific Institute, Milan, Italy 10Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
Correspondence: Ivan.Stamenkovic@chuv.ch; nicolo.riggi@chuv.ch
*Gaylor Boulay and Luisa Cironi contributed equally to this work
†Sara P Garcia and Shruthi Rengarajan contributed equally to this work
Miguel N Rivera, Ivan Stamenkovic, and Nicolo Riggi are senior authors
© 2020 Boulay et al. https://doi.org/10.26508/lsa.202000808 vol 4 | no 2 | e202000808 1 of 17
on 11 January, 2021life-science-alliance.org Downloaded from 
http://doi.org/10.26508/lsa.202000808Published Online: 23 December, 2020 | Supp Info: 
et al, 1999; Nagai et al, 2001). SS18 is a component of the mamma-
lian chromatin remodeling complex switch/sucrose non-fermentable
(SWI/SNF also knownasBRG1/BRM-associated factor, BAF) (Wang et al,
1996a, 1996b; Kadoch & Crabtree, 2013), which facilitates transcrip-
tion by increasing chromatin accessibility at promoter and enhancer
regions. In contrast, SSX1/2 belongs to a family of transcriptional re-
pressors that co-localize with polycomb group proteins (PcG), including
BMI1 and RING1B (Hale et al, 2019; Johansen & Gjerstorff, 2020). The
two constituents of the fusion protein are thus associated with op-
posing effects on chromatin regulation and the integration of their
activities appears to provide the key toward establishing the oncogenic
signaling network that generates SyS. Biochemical studies have shown
that SS18-SSX replaces wt SS18 in the BAF complex and alters its
composition by ejecting the tumor suppressor SNF5/BAF47 (Kadoch &
Crabtree, 2013). The resulting effect is the redirection of the newly
constituted BAF complexes from enhancers to PcG domains to relieve
polycomb repressor complex (PRC)2–mediated repression of bivalent
target promoters (McBride et al, 2018). Recent functional genomic
experiments have also uncovered physical interaction between SS18-
SSX and the histone demethylase KDM2B, a component of a non-
canonical polycomb repressive complex 1 (ncPRC1.1), which leads to
aberrant reactivation and expression of PcG target genes that are
required for transformation (Banito et al, 2018a). An additional re-
pressive role for SS18-SSX, which leads to PRC2 recruitment to ATF2
target genes, has also been proposed (Su et al, 2012).
Given the importance of epigenetic events as drivers of its
pathogenesis, chromatin regulators constitute potentially attractive
therapeutic targets for SyS. Accordingly, recent studies suggest that
small-molecule–mediated degradation of the BAF component BRD9
can reverse oncogenic gene regulation in SyS (Brien et al, 2018; Michel
et al, 2018). However, the development of new anticancer therapies is
hindered by the paucity of reliable pre-clinical models. Patient-
derived tumor organoids have emerged as a powerful system for
modeling key biological properties of human carcinomas and their
response to therapy (Drost & Clevers, 2018). Whereas organoids from
human sarcomas have generally been challenging to establish, we
have shown that 3D organoids derived from primary Ewing sarcomas
recapitulate key native tumor features more closely than cell lines
maintained in 2D culture, including inter- and intra-tumor hetero-
geneity, cellular plasticity and response to therapy (De Vito et al, 2012;
Cornaz-Buros et al, 2014).
In the present study, we sought to generate primary models of
SyS that capture its regulatory landscape and provide insight into
its driver mechanisms and epigenetic dependencies. We therefore
produced a set of patient-derived SyS organoids and assessed their
genome-wide regulatory features through chromatin profiling. Our
observations reveal that expression of SS18-SSX in both organoids
and mesenchymal precursor cells is associated with a distinctive
distribution of the BAF complex and the uncoupling of PRC1 and
PRC2. Together, these events initiate a SyS-specific oncogenic
program that is completely reversible upon SS18-SSX silencing,
suggesting that a pharmacological approach aimed at epigenetic
regulatory events may offer realistic therapeutic opportunities in
established tumors. Accordingly, we found SyS cells to be highly
vulnerable to the depletion of ubiquitin-specific protease 7
(USP7), a member of ncPRC1 involved in maintaining SyS cell
proliferation. Taken together, our results show that the chromatin
landscape of Sys organoids not only reflects the key pathogenic
mechanisms that lead to SyS but is also linked to specific epigenetic
dependencies.
Results
Primary synovial sarcoma organoids have a distinctive pattern of
BAF complex distribution
tTo mimic primary tumor features as closely as possible, we de-
veloped organoids from primary synovial sarcoma samples removed
at surgery. Tumor organoids have consistently shown superiority to
cell lines in providing adequate models for the study of tumor bi-
ology (Drost & Clevers, 2018) but have not previously been estab-
lished from synovial sarcoma. We generated organoids from four
primary SyS (SyS1-4) and expanded them in serum-free conditions
to avoid any serum-related epigenetic alteration (Dangles-
Marie et al, 2007) (Fig 1A). Expression of SS18-SSX in all four
organoids was confirmed by qRT-PCR (Fig 1B) and by chromatin
analyses using the H3K36me3 histone mark in the SSX1 39 terminal
region as an indicator of transcription (Fig 1C). To determine SyS-
specificity of the observed chromatin patterns, we used two sets of
controls: two primary Ewing sarcoma organoids, established under
conditions identical to those used to generate SyS organoids (Suva
et al, 2009), and three different non-transformed human cell types,
including primary mesenchymal stem/stromal cells (MSCs), em-
bryonic lung fibroblasts (MRC5) and mesothelial cells (MET5A). We
determined the epigenomic profiles of the primary organoids and
non-transformed cells by genome-wide ChIP-seq analysis of the
histonemarks H3K4me1, H3K4me3, H3K9ac, H3K27ac, H3K27me3, and
H3K36me3. Because SS18-SSX becomes integrated into the BAF
complex (Kadoch & Crabtree, 2013), we also assessed BAF-binding
sites using antibodies against the core ATPase BAF members
SMARCA2/4.
ChIP-seq analysis revealed BAF ATPases to be located within
domains whose breadth was far greater in SyS organoids than in any
of the control cells (median width: 2,198 versus 628 bp) (Fig 1D). The
observed difference in domain size was even more striking when the
broadest 25% of BAF domains from each cell type were compared
(Q4, Figs 1E and S1A), with amedian width in excess of 5 kb in SyS cells
but below 2 kb in all the other cells, including those from Ewing
sarcoma-derived organoids. These differences were less striking
among the narrowest 25% of BAF domains (Q1, Figs 1F and S1B) and
SyS organoids contained fewer BAF sites than control cell types (Figs
1G andH and S1C). Consistent with the ability of SS18-SSX to create an
aberrant BAF complex, as observed in established synovial sarcoma
cell lines (Kadoch & Crabtree, 2013), our observations suggest that
tumor-specific genome-wide BAF distribution is a major feature of
the epigenetic landscape in SyS organoids.
Broad BAF complex domains are associated with active chromatin
states in synovial sarcoma organoids
To identify the chromatin states that are specifically associated
with BAF in SyS, we focused on SMARCA2/4 sites shared among our
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Figure 1. BAF complex is organized in unusually broad domains in primary synovial sarcoma organoids.
(A)Micrographs show the four patient-derived synovial sarcoma 3D organoid cultures. Scale bar: 200 μm. (B) Schematic representation of the SS18-SSX fusion gene (left)
and RT-PCR products showing the detection of SS18-SSX in patient-derived synovial sarcoma organoids. Water is used as a negative control and HSSYII cell line as a
positive control. (C) H3K36me3 ChIP-seq signals at the SSX1 locus show active transcription of the 39 terminal region that becomes fused to SS18 to form the fusion gene
SS18-SSX in patient-derived synovial sarcoma organoids. (D) Violin plots show the overall distribution of peak widths for SMARCA2/4–binding sites in four synovial
sarcoma patient-derived tumor organoids, two Ewing sarcoma patient-derived tumor organoids (EwS1 and 2) and four control cell types. (E, F) Boxplots show the
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four SyS organoidmodels. Based on themarked differences in domain
breadth between SyS and control cells (Fig 1), we first analyzed the
broadest BAF domain quartile (Fig 2A and B, Q4, 3,430 peaks). These
domains had amedian size above 5 kb in all organoids (Figs 1E and 2A)
and comparable genomic distribution (Fig S1A left and Fig 2B). We then
integrated the genome-wide profiles, obtained by ChIP-seq, of our
panel of histonemodifications to generate a functional chromatinmap
in SyS organoids. Consistent with previous observations in SyS cell
lines (Kadoch et al, 2017), our analysis revealed mutually exclusive
distribution of broad BAF domains and the polycomb-dependent
H3K27me3 mark (Fig 2C). BAF complexes were almost exclusively as-
sociated with active chromatin states as indicated by the presence of
H3K4me1, H3K4me3, H3K9ac, and H3K27ac histonemarks (Fig 2C and D).
These observations held true at both proximal and distal sites (Fig 2D),
and upon independent analysis of H3K27me3 PRC2 domains (Figs 2C–F
and S2A and B, compare ChIP-seq levels between BAF domains [Fig 2D]
and H3K27me3 domains [Fig S2B]). The same analyses of the narrowest
25% of BAF domains in SyS (Q1) showed increased localization to
proximal sites (Fig S2C) but a similar association with active chromatin
regions (Fig S2C and D). Thus, both the distinctive broad BAF domains
and the more typical narrow peaks are associated with active chro-
matin devoid of PRC2 activity in SyS organoids.
Broad BAF domains are associated with the expression of a
tumor-specific gene signature in synovial sarcoma
To investigate the functional effect of altered BAF domains, we
performed gene expression profiling of the four SyS organoids and
of primary human MSCs, a candidate SyS cell of origin (Cironi et al,
2009; Garcia et al, 2012). We first compared the genes associated
with either broad (Q4) or narrow (Q1) BAF domains identified in SyS
(Fig 2A) and found no significant differences in relative expression
levels (Fig S3A and B). We next interrogated possible Q4 BAF domain
association with a distinctive gene expression signature in SyS by
comparing the gene expression profiles of our SyS organoids and
primary MSC cultures. Using a fourfold expression change cutoff, we
identified 1,678 and 1,149 transcripts displaying, respectively, higher
and lower expression in SyS compared to MSCs (Figs 3A and S3C).
Remarkably, the genes that were preferentially expressed in SyS
organoids tended to be linked to broad BAF domains compared to
those that were more highly expressed in MSCs (median 3.27 versus
1.90 kb, P-value 2.2 × 10−16) (Fig 3B). The same held true regarding the
percentage of genes associated with broad (Q4) and narrow (Q1)
BAF domains: a significantly higher percentage of genes that were
more strongly expressed in SyS was associated with Q4 than with Q1
domains (Fig 3C, left), whereas no difference in domain association
was detected among the genes that were more highly expressed in
MSCs in either SyS (Fig 3C right) or in MSCs themselves (Fig S3D).
We then applied the same strategy to a set of genes that were
differentially expressed between primary SyS and a panel of six
unrelated sarcoma types profiled by the The Cancer Genome Atlas
(TCGA) consortium (Cancer GenomeAtlas ResearchNetwork. Electronic
address edsc, Cancer Genome Atlas Research Network, 2017). We first
identified transcripts that are preferentially expressed in pri-
mary SyS compared to all the other sarcomas (fivefold expres-
sion cutoff, Figs 3D and S3E), and then applied the resulting
signature to interrogate the corresponding BAF domain size in
our organoids. Once again, we observed the genes preferentially
expressed in SyS to be associated with broader BAF domains,
whereas no such difference was detected among the transcripts
more highly expressed in unrelated sarcomas (Figs 3E and S3F).
The same enrichment in broad (Q4) BAF domainswas observed (Fig 3F)
among individual SyS-high gene signatures compared to those of each
of the unrelated sarcomas included in the TCGA dataset (fourfold
expression change cutoff Fig S3G). Taken together and consistent with
observations in SyS cell lines (Kadoch et al, 2017), these observations
suggest a prominent and specific role for broad BAF domains in
establishing andmaintaining the oncogenic gene expression signature
that defines SyS cell identity.
SS18-SSX expression leads to reversible retargeting of the BAF
complex, removing the H3K27me3 repressive mark
The SS18-SSX protein has been shown to evict and replace both wt
SS18 and SNF5 in BAF, creating an altered nucleosome remodeling
complex that displays neomorphic oncogenic properties (Kadoch &
Crabtree, 2013). We therefore reasoned that the distinctive BAF
domains observed in SyS organoids may arise as a direct result of
SS18-SSX expression. To date the chromatin remodeling events
induced by SS18-SSX have been primarily addressed by depleting
the fusion protein from SyS cell lines. Such an approach, however,
does not allow assessment of the initial effect of the fusion protein
in a naı̈ve, permissive cellular context. To gain insight into the early
events that drive SyS pathogenesis, we stably expressed V5-tagged
SS18-SSX1 in primary mouse C3H10T1/2 cells, which we have pre-
viously shown to provide a permissive and biologically relevant
cellular model for the expression of the fusion gene (Cironi et al,
2016). C3H10T1/2 cells stably expressing SS18-SSX1-V5 and their
corresponding control counterparts were profiled by ChIP-seq
using the same anti-SMARCA2/4 and anti-histone mark anti-
bodies that we applied to our SyS organoid models. Genomic
distribution of the fusion protein was determined using a
specific anti-V5 antibody.
Our initial analysis revealed SS18-SSX1 distribution to be remi-
niscent of that of the broadest Q4 BAF domains in SyS organoids.
First, the fusion protein–binding sites identified in C3H10T1/2-SS18-SSX1
cells displayed an unusual breadth (with a mean of ~9 kb, Fig 4A).
Second, the genomic distribution of SS18-SSX1 recapitulated that of
the broadest Q4 BAF domains in SyS organoids, with a significant
enrichment at distal regulatory elements (Figs 4B and S4A). Third,
consistent with its role as a core member of the BAF complex,
marked increases in SMARCA2/4 ChIP-seq signals were observed
at SS18-SSX1–binding sites (Fig 4C). Importantly, our analysis of
genome-wide BAF domain distribution revealed increased domain
distribution of peak widths of the (E) broadest BAF complex domains (Q4) and the (F) narrowest BAF complex domains (Q1) identified in each cell type separately. (G) Pie
charts show the genomic locations of SMARCA2/4–binding sites in four synovial sarcoma patient-derived tumor organoids. (H) Examples of broad BAF complex domains
identified in synovial sarcoma at loci associated with BMP4 and SOX2. See also Fig S1.
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Figure 2. BAF complex broad domains are associated with active chromatin states in synovial sarcoma.
(A) Boxplot showing the distribution of peak widths for shared BAF complex domains in synovial sarcoma per quartile. (B) Pie chart showing genomic locations of the
broadest BAF complex domains shared among synovial sarcoma tumor organoids. (C) Heat maps showing average ChIP-seq signals for SMARCA2/4 and the indicated
histone modifications at broad BAF complex domains (left) and polycomb H3K27me3 domains (right) in synovial sarcoma. (D) Heat maps showing ChIP-seq signals for
SMARCA2/4, H3K4me1, H3K4me3, H3K27ac, and H3K27me3 at distal sites (top) and promoters (bottom) for broad BAF complex–binding sites in synovial sarcoma. Marks of
activity (H3K4me1, H3K4me3, and H3K27ac) are detected but not the polycomb repressive mark H3K27me3. 20-kb windows centered on SMARCA2/4–binding sites are
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width in C3H10T1/2-SS18-SSX1 cells (Q4, median width 4,827 versus 1,682
bp in, respectively, SS18-SSX1–expressing versus control cells, P-
value 2.2 × 10−16) (Fig 4D). These remodeling events were also as-
sociated with a decrease in the overall number of BAF sites (Fig S4B),
recapitulating our observations in primary SyS organoids. Interest-
ingly, although the fusion protein could increase the width of pre-
existing BAF domains, most broad BAF domains were constituted de
novo upon SS18-SSX induction (Fig S4C). Taken together, these results
support the possibility that reorganization and retargeting of the BAF
complex in SyS is a direct effect of SS18-SSX.
Next, to evaluate the functional effect of altering the BAF complex
in a naı̈ve cellular context, we assessed the original chromatin states
and genomic distribution of the 4,877 sites to which SS18-SSX is tar-
geted in C3H10T1/2 control cells before the expression of the fusion
shown. (E) Representative example of BAF complex broad domain and associated histone modifications at the locus associated with BMP5 in synovial sarcoma tumor
3D cultures. (F) Representative example of a polycomb domain in synovial sarcoma organoids. Strong signals are detected for the polycomb repressivemark H3K27me3 but
not for SMARCA2/4. See also Fig S2.
Figure 3. Broad BAF complex domains are enriched at genes specifically expressed in synovial sarcoma.
(A) Heat map showing the genes that are differentially expressed between synovial sarcoma organoids and mesenchymal stem cells (fourfold differential expression).
(A, B) Boxplot showing the distribution of peak widths for BAF complex domains in synovial sarcoma 3D cultures at genes highly expressed in synovial sarcoma (purple)
and at genes highly expressed inmesenchymal stem cells (yellow) identified in (A). Median peak width values are indicated. (A, C) Barplot showing the percentage of genes
identified in (A) bound by either a broad (Q4) or a narrow BAF domain (Q1) in synovial sarcoma organoids. (D) Boxplot showing the genes that are differentially
expressed between primary synovial sarcomas and other sarcomas from The Cancer Genome Atlas (fivefold differential expression). (D, E) Boxplot showing the peak
width distribution of BAF complex domains in synovial sarcoma organoids at genes highly expressed in synovial sarcoma (purple) versus the genes highly expressed in
other sarcomas (green shades) identified in (D). Median values are indicated. (F) Barplot showing the percentage of genes identified by comparing primary synovial
sarcomas to other sarcomas from The Cancer Genome Atlas independently (20-fold differential expression) bound by either a broad (Q4) or a narrow BAF domain (Q1) in
synovial sarcoma organoids. * indicates P-value < 0.05, ** indicates P-value < 0.01 for a Welch two-sample t test with a 95% confidence interval. See also Fig S3.
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Figure 4. SS18-SSX can induce broad BAF complex domains and evict polycomb activity.
(A) Violin plot showing the overall distribution of peak widths for SS18-SSX–binding sites in C3H10T1/2 cells stably expressing the fusion protein in two independent
ChIP-seq experiments. (B) Pie chart showing genomic locations of common SS18-SSX–binding sites in C3H10T1/2 cells stably expressing the fusion protein. (C) Left:
Composite plot showing the average SMARCA2/4 ChIP-seq signals at SS18-SSX–binding sites in control cells (black) and cells expressing SS18-SSX (purple). Right: Heat
maps showing ChIP-seq signals for SMARCA2/4 and V5 (SS18-SSX) at SS18-SSX–binding sites in control and SS18-SSX–expressing C3H10T1/2 cells. (D) Boxplot showing
the distribution of peak widths for SMARCA2/4 in control (left) and SS18-SSX–expressing cells (right) per quartile. (E)Heatmap showing average initial ChIP-seq signals for
the indicated histonemodifications in control cells at SS18-SSX–binding sites. The six indicated categories of binding sites were obtained using hierarchical clustering and
manually annotated based on chromatin states. (F) Bar charts showing genomic locations (left) and annotation of CpG content (right) for each category of SS18-
SSX–binding sites. (E, G) Heat map showing changes of the indicated histone modifications at each category of SS18-SSX–binding sites identified in (E). Average log2 fold
changes in ChIP-seq signals are displayed. (E, H) Heat maps showing ChIP-seq signals for V5 (SS18-SSX), SMARCA2/4, H3K27me3, H3K4me1, and H3K27ac at SS18-
SSX–binding sites that bore the polycombmark H3K27me3-in control C3H10T1/2 shown in (E) before SS18-SSX expression. 20-kb windows centered on SS18-SSX–binding
sites are shown. (I) Representative example of broad BAF complex domains replacing preexisting H3K27me3 polycomb domains. See also Fig S4.
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protein. We found that SS18-SSX is preferentially recruited to two
distinct chromatin states: those bearing the polycomb mark
H3K27me3 (H3K27me3 only: 1,338 sites, 27.4%; bivalent domains: 835
sites, 17.1%), and primed enhancers, marked by a high H3K4me1 to
H3K27ac ratio (1,405 sites, 28.8%) (Fig 4E). It must be noted, however,
that the sites marked by H3K27me3 to which SS18-SSX is recruited
represent 6.54% of all the sites bearing H3K27me3. A lower pro-
portion of SS18-SSX1–targeted sites displayed chromatin features
of active promoters (293), active enhancers (539), and no signal-
desert regions (467), underscoring the unique ability of the fusion
protein to bind to a wide range of established active, poised or
repressive chromatin states (Figs 4E and S4D). The relatively high
proportion of SS18-SSX–binding sites pre-marked with H3K27me3
prompted us to investigate whether H3K27me3 itself might favor the
recruitment of the fusion protein. To this end, we treated C3H10T1/2
cells with the selective EZH2 inhibitor EPZ6438 for 8 d prior to SS18-
SSX expression. qPCR transcript analysis of a panel of SS18-SSX
target genes, whose distal regulatory elements are marked by
H3K27me3 in wild type C3H10T1/2 cells, failed to reveal differences
between control and EPZ6438-treated cells upon SS18-SSX expres-
sion, despite robust reduction of H3K27me3marks in treated cells (Fig
S4E and F).
Because SS18-SSX has been recently shown to be recruited to
unmethylated DNA CpG islands through direct interaction with the
chromatin regulator KDM2B (Banito et al, 2018b), we interrogated
the potential genomic overlap with CpG-enriched regions of the
4877 SS18-SSX1 direct binding sites identified in C3H10T1/2 cells. As
expected, 73.4% of the 293 sites displaying chromatin features of
active promoters harbored at least one CpG island, whereas only a
minority of polycomb-marked regions (14.2%) and distal regulatory
elements (3.15%) contained CpG islands (Fig 4F). These results
suggest involvement of more than a single molecular mechanism in
the recruitment of the fusion protein to its DNA target sites, which,
in addition, may at least in part be cell type– and chromatin
state–dependent. Changes in chromatin state and activity of the
different categories of SS18-SSX–binding sites were then assessed
upon expression of the fusion protein. Although SS18-SSX binding
induced an active chromatin environment at virtually all sites (Fig
4G), the most significant changes occurred at sites that contained
the repressive H3K27me3mark (polycomb and bivalent domains, Fig
4E). These sites underwent complete removal of H3K27me3, fol-
lowed by generation of fully active distal regulatory elements
displaying the enhancer marks H3K4me1 and H3K27ac (Fig 4G).
Finally, to assess the reversibility of the chromatin changes
mediated by SS18-SSX, we took advantage of the lox sites flanking
the SS18-SSX1 cDNA sequence in our lentiviral vector system to
genetically knockout the fusion gene in target cells. We therefore
expressed a recombinant CRE in SS18-SSX–expressing C3H10T1/2
cells andmeasured the ensuing epigenetic changes. The same cells
infected with the corresponding empty vector provided the control.
After SS18-SSX1 protein depletion (Fig S5A), we observed nearly
complete reversion of the chromatin states to their initial con-
figuration in naı̈ve C3H10T1/2 cells (Figs 4H and I and S5B). This
included the complete loss of activation marks and restoration of
the repressive H3K27me3 domains at SS18-SSX–binding sites. Re-
markably, SS18-SSX depletion also restored the original BAF
complex width observed in naı̈ve C3H10T1/2 cells (Fig S5C), further
highlighting the tight functional relationship between altered BAF
domain deposition and SS18-SSX expression. Taken together, our
results reveal how expression of the SS18-SSX fusion protein in a
permissive naı̈ve cellular context results in a cascade of epigenetic
changes that include retargeting of the oncogenic BAF complex to
new genomic sites, and the generation of de novo active chromatin
regions that reshape the epigenetic landscape of SyS precursor
cells.
SS18-SSX target gene activation is primarily mediated by the
reversible eviction of H3K27me3 repressive activity
To determine the relative contribution of SS18-SSX–dependent BAF
complex redistribution to target gene activation, we performed
whole-genome RNA-seq expression profiling of SS18-SSX1–
expressing and control C3H10T1/2 cells. Expression of the fusion
protein resulted in the robust induction of 278 and repression of 113
transcripts (Fig 5A, fourfold change cutoff and false discovery rate <
0.05). Induced genes were 2.4-fold more likely to be associated with
neighboring SS18-SSX binding (Fig 5B), which wasmildly enriched at
proximal elements (Fig 5C). Consistent with our preceding results,
we found that most fusion protein–binding sites associated with
induced transcripts had a repressive chromatin configuration
before SS18-SSX recruitment (polycomb-only or bivalent, Fig 5D,
right). Binding of the fusion protein was followed by complete
removal of the H3K27me3 mark and the concomitant deposition of
the chromatin features of active proximal and distal regulatory
elements (Fig 5E, right). In contrast, the chromatin states at fusion
protein–binding sites associated with repressed transcripts were
enriched in primed or active enhancer marks (Fig 5D, left) and did
not undergo substantial changes upon SS18-SSX recruitment (Fig
5E, left). Finally, consistent with the observed chromatin state re-
versibility upon SS18-SSX depletion (Fig 4H and I), CRE expression in
C3H10T1/2SS18-SSX1 cells resulted in a significant reversion of their
transcriptional profile to that preceding SS18-SSX introduction (Fig
5F), the lack of complete reversion being most likely due to in-
complete depletion of SS18-SSX. Taken together, these results
highlight the notion that PcG domain presence, although not a
requisite for SS18-SSX recruitment, is linked to the most significant
SS18-SSX-induced chromatin changes associated with transcrip-
tional activation. Moreover, both chromatin and gene expression
changes remained reversible upon SS18-SSX depletion, suggesting
that detailed understanding of the mechanisms that underlie the
observed plasticity may provide a tangible opportunity to block the
oncogenic properties of the fusion protein.
SS18-SSX orchestrates functional PRC1–PRC2 complex uncoupling
Similar to the aberrant fusion proteins that drive the development
of other human sarcomas, SS18-SSX lacks an enzymatic domain
amenable to direct pharmacological targeting. Accordingly, de-
tailed understanding of the chromatin remodeling events that drive
transcriptional changes at the binding sites of the fusion protein
and their reversibility upon SS18-SSX depletion are critical toward
identifying new tumor-specific therapeutic strategies. Our experi-
ments so far have shown a pattern of mutual exclusivity between
SS18-SSX binding and H3K27me3 deposition, suggesting genome-wide
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functional antagonism between PRC2 and oncogenic BAF complexes.
Consistent with this notion, binding of the BAF complex has been
shown to result in the rapid eviction of both canonical PCR1 and PRC2
complexes in mouse embryonic fibroblasts through the ATPase
activity of SMARCA4 (Stanton et al, 2017). More recently, SS18-SSX itself
has been found to recruit ncPRC1.1 at its binding sites in SyS cells
(Banito et al, 2018b). We reasoned that a possible explanation for
these observationsmay be linked to the functional uncoupling of the
PRC1–PRC2 complexes at the fusion protein–binding sites in SyS,
starting with eviction of PRC2 followed by the recruitment of ncPRC1.1
and transcriptional activation. An analogous uncoupling event has
been previously shown to induce gene expression in models of
epidermal and leukemia stem cells (van den Boom et al, 2016; Cohen
et al, 2019).
To test this hypothesis, we used ChIP-seq to profile the PRC1 core
member RING1B and its related H2AK119ub histone mark in control
and SS18-SSX–expressing C3H10T1/2 cells. We initially focused on
the 1338 PRC2-marked genomic regions that undergo H3K27me3
removal upon SS18-SSX expression and compared the signal levels
of RING1B, H2AK119ub, and H3K27me3 between control and SS18-
SSX–expressing cells. Remarkably, binding of the fusion protein
increased the signal of both RING1B and the H2AK119ub mark at
these genomic regions, concomitant to nearly complete removal of
H3K27me3 (Fig 6A and B). Importantly, SS18-SSX recruited ncPRC1 to
all of its binding sites and not exclusively to those bearing the
H3K27me3 mark (Fig S6). However, neither RING1B nor H2AK119ub
global protein levels were increased in SS18-SSX–expressing cells
(Fig S7A). Consistent with our previous results, we found these
chromatin changes to be reversible upon CRE-mediated depletion
of the fusion gene in C3H10T1/2 cells, underscoring their plasticity
(Figs 6B and S7B). We also identified strong RING1B and H2AK119ub
ChIP-seq signals at the broad Q4 SMARCA2/4 domains in SyS
organoids at similar or even higher levels than H3K27me3 marked
polycomb sites (Fig 6C and D). Furthermore, similar to our initial
observations on BAF complex binding patterns (Fig 4C and D), SS18-
SSX augmented RING1B domain width upon expression in C3H10T1/2
cells (Fig 6E, median width 1,229 versus 756 bp in, respectively, SS18-
SSX1–expressing versus control cells, P-value 2.2 × 10−16), and in both
experimental models, the broadest RING1B domains were the most
enriched at SS18-SSX bound genomic locations in C3H10T1/2 cells
Figure 5. SS18-SSX can induce strong gene expression changes through reversible chromatin modification mechanisms.
(A) Left: Volcano plot showing gene expression changes upon stable SS18-SSX expression in C3H10T1/2 cells. Red dots indicate genes differentially expressed (at least
fourfold change and adjusted P-value < 0.05). Right: Representative examples of genes strongly activated upon SS18-SSX expression. (B) Barplot showing the percentage
of up- and down-regulated genes upon SS18-SSX expression associated with SS18-SSX binding. (C) Bar charts showing genomic locations (left) and annotation of CpG
content (right) of SS18-SSX–binding sites associated with up- and down-regulated genes. (D) Bar chart showing the distribution of initial chromatin states as defined in
Fig 4E at SS18-SSX–binding sites associated with up- and down-regulated genes. (E) Heat map showing ChIP-seq changes for the indicated histone modifications at SS18-
SSX–binding sites associated with up- and down-regulated genes. (F) Heat map showing gene expression changes upon SS18-SSX expression in C3H10T1/2 cells (left) and
upon SS18-SSX removal (right). See also Figs S5 and S6.
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Figure 6. SS18-SSX expression results in a functional PRC1–PRC2 complex uncoupling at its genomic binding sites.
(A) Composite plots for RING1B, H2AK119ub, and H3K27me3 signals at 1338 SS18-SSX–binding sites, initially bearing the PRC2 repressive mark, showing that expression of
the fusion protein in C3H10T1/2 cells results in an increase in the RING1B and H2AK119ub signals, and the removal of the H3K27me3mark. (A, B) Heat maps for RING1B and
H2AK119ub signals at the same 1338 SS18-SSX–binding sites as in (A), illustrating the reversibility of the chromatin remodeling pattern upon CRE-mediated SS18-SSX
depletion in C3H10T1/2 cells. 20-kb windows centered on SS18-SSX–binding sites are shown. (C) Boxplot analysis of the RING1B, H2AK119ub, and H3K27me3 ChIP-seq
signals in primary SyS 1 organoids, confirming the presence of PRC1 and the related H2AK119ub mark, but not the PRC2 mark H3K27me3, at broad BAF domains in primary
SyS tumor models. (D) Representative example of RING1B recruitment and H2AK119ub deposition at a broad BAF complex domain in SyS organoid cultures. (E) Boxplot
showing the distribution of peak widths for RING1B in control and SS18-SSX–expressing C3H10T1/2 cells. (F) Barplot depicting the percentage of RING1B-binding sites in
each width quartile that overlap with the broadest SMARCA2/4 domains in SyS organoids. (G) Proximity ligation assay analyses demonstrate direct interactions between
SS18-SSX and the PRC1 subunits RING1B and RYBP, but not the PRC2 core member EZH2, in C3H10T1/2 cells. (H) Proximity ligation assay analysis of SS18-SSX–expressing or
control C3H10T1/2 cells confirming that the expression of the fusion protein enhances the assembly of the ncPRC1, as indicated by the increase in interactions between
its core members RING1B and RYBP. (I) Heat map showing ChIP-seq signals for RYBP at SS18-SSX–binding sites in C3H10T1/2 cells. 20-kb windows centered on SS18-
SSX–binding sites are shown. (J) Representative example of RING1B and RYBP recruitment at SS18-SSX–binding sites in C3H10T1/2 cells. (K) A mechanistic model of SS18-
SSX chromatin remodeling activity in SyS. After SS18-SSX expression, the PRC2 repressive mark H3K27me3 is replaced by the active histone modifications H3K4me1 and
H3K27ac. The concomitant recruitment of a non-canonical PRC1 by the fusion protein leads to PRC2-PRC1 uncoupling, H2AK119ub deposition and target gene activation.
*** indicates P-value < 0.0001. Statistical analyses were performed by t test. See also Fig S7.
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(Fig S7C) and at the broad Q4 SMARCA2/4 domains in SyS organoids
(Figs 6F and S7D).
We then used proximity ligation assay (PLA) to validate the in-
teraction between the fusion protein and the PRC1 complex
members RING1B and RYBP on the one hand and the absence of
interaction between SS18-SSX and the PRC2 core member EZH2 on
the other (Fig 6G). Whereas RING1B is a core member of all PRC1
complex variants, RYBP is primarily associated with ncPRC1 com-
plexes. We therefore reasoned that by recruiting de novo PRC1
variants at its binding sites, SS18-SSX might increase detectable
interactions between RING1B and RYBP. To test this hypothesis, we
analyzed the PLA interaction signal between RING1B and RYBP in
control and SS18-SSX–expressing C3H10T1/2 cells, and identified a
marked increase in the RING1B–RYBP interactions in the presence
of the fusion protein (Fig 6H), which was not observed between the
PRC2 core members EED and EZH2 (Fig S6E). Consistent with these
observations, RYBP signals detected by ChIP-seq were also strongly
increased at SS18-SSX–binding sites in C3H10T1/2 cells (Fig 6I and J).
In contrast to RING1B, cellular expression of RYBP was increased by
SS18-SSX, which may reflect its implication in facilitating the tran-
sition of canonical PRC1 to ncPRC1 at the fusion protein–binding sites
(Fig S7A). Taken together, these results demonstrate that SS18-SSX
induces functional uncoupling of the canonical PRC2-PRC1 com-
plexes at its direct binding sites, by recruiting a ncPRC1 variant that
sustains transcriptional activation (Fig 6K).
USP7 depletion is an epigenetic vulnerability in synovial sarcoma
Because reconfiguration of chromatin remodeling complexes may
provide new opportunities to uncover epigenetic vulnerabilities, we
interrogated the DepMap database of cancer dependencies for SyS-
selective vulnerability to inactivation of any of the six PRC1 variants
(Vidal & Starowicz, 2017). Comparison of RNAi-induced cell vul-
nerabilities between SyS cell lines and all other cell lines revealed
that among the 21 genes analyzed, USP7 depletion produced a
consistent and robust detrimental effect that was significantly
more pronounced in SyS (Fig 7A). Ubiquitin-specific protease 7
(USP7) is a member of the deubiquitinase (DUBs) family and has an
important implication in cancer development by altering the DNA
damage response, apoptosis and cell cycle control (Nicholson and
Suresh Kumar, 2011; Smits & Freire, 2016). Functionally, USP7 par-
ticipates in stabilizing ncPRC1.1, in which it acts as a regulator of
H2AK119ub deposition and gene expression (Wheaton et al, 2017).
To test whether USP7 may represent a druggable epigenetic
vulnerability of SyS directly linked to SS18-SSX, we tested the
genome-wide localization of USP7 by ChIP-seq and found strong
signals at SS18-SSX–binding sites in C3H10T1/2 cells (Fig 7B and C).
Although no change in the USP7 protein level was observed upon
SS18-SSX expression (Fig S8A), the fusion protein induced a re-
markable reorganization of USP7-binding sites genome-wide (Fig
S8B and C). Consistent with these results, we also found evidence of
interaction between SS18-SSX and USP7 by PLA in C3H10T1/2 cells
and the HSSYII SyS cell line that harbors an endogenous HA-tagged
SS18-SSX protein (Banito et al, 2018a) (Fig 7D and E). These ob-
servations prompted us to validate the effect of USP7 depletion in
SyS cells. Using two different single guide RNAs specifically tar-
geting the USP7 coding sequence we achieved significant reduction
in USP7 expression in two SyS cell lines, HSSYII and SYO1 (Fig S8D).
As previously observed in leukemia, USP7 depletion in SyS resulted
in the partial disassembly of the ncPRC1 complex, as illustrated by
the marked decrease in interactions between RING1B and RYBP in
the SyS cell line HSSYII (Fig 7F). Importantly, loss of USP7 did not
affect the expression levels of SS18-SSX in either cell line (data not
shown). Consistent with its selective detrimental effect observed in
DepMap, USP7 depletion produced a significant decrease in pro-
liferation of the SyS HSSYII and SYO1 cell lines, but not of the Ewing
sarcoma A673 and RDES lines, despite comparable baseline protein
expression levels (Fig 7G). Accordingly, synovial sarcoma cells (as
represented by two cell lines and one organoid model) displayed
markedly higher sensitivity to incremental doses of the USP7 in-
hibitor FT827 than Ewing sarcoma cells (Fig S8E). Taken together,
these results identify an epigenetic dependency of SyS cells to USP7
depletion that is directly linked to the molecular function of SS18-
SSX.
Discussion
In the present work, we generated primary organoid models to
study the mechanisms that drive SyS. Whereas cell lines have since
their first establishment provided the most widely used means
to study diverse cancer types, there is increasing evidence that
organoids reflect key biological properties of primary tumors more
accurately, including response to therapy and intra-tumor het-
erogeneity (Tuveson & Clevers, 2019; Schutgens & Clevers, 2020).
Consistent with this notion, our work on primary Ewing sarcomas
has shown that organoids can be valuable tools for elucidating
mechanisms of tumor initiation and progression in sarcomas (De
Vito et al, 2012; Cornaz-Buros et al, 2014). Because SyS is driven by an
aberrant chromatin regulator, we used genome-wide chromatin
profiling to map the epigenetic landscape of SyS organoids and
define the chromatin remodeling events induced by the SS18-SSX
fusion protein. Our results show that SS18-SSX establishes a dis-
tinctive SyS chromatin landscape by retargeting BAF complexes to
new genomic locations, from which the repressive histone modi-
fication H3K27me3 deposited by PRC2 is removed and to which a
ncPRC1 complex is recruited. Although our observations suggest
that SS18-SSX recruits the ncPRC1.1 complex containing RING1B,
RYBP, and USP7, further investigation will be required to elucidate
the exact composition and function of this protein complex in SyS.
Importantly, we find that these major chromatin changes are com-
pletely reversible upon SS18-SSX removal, suggesting that their ef-
fectors constitute potentially attractive therapeutic targets.
Our results support recent studies that showed retargeting of the
oncogenic BAF complex by SS18-SSX in SyS cell lines and its an-
tagonistic effect on the H3K27me3 repressive mark (Kadoch &
Crabtree, 2013; Kadoch et al, 2017). Intriguingly, short-term re-
cruitment experiments show that both wild type BAF and SS18-
SSX–containing BAF complexes can directly and rapidly evict PRC1
and PRC2 (Kadoch & Crabtree, 2013; Kadoch et al, 2017). The re-
cruitment of a ncPRC1 observed at later time points in our work may
thus occur after the initial removal of PRC1 and PRC2. Alternatively,
the recruitment of ncPRC1 may occur more readily in the chromatin
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environment specific to precursor cells such as CH310T1/2. Whereas
polycomb group proteins are traditionally considered to be epigenetic
repressors, recent evidence suggests a more complex scenario in which
ncPRC1 plays an important physiological role associated with gene ac-
tivation (Cohenet al, 2019;Wang&Yi, 2019). For example, loss of ncPRC1 in
epithelial cells of the skin results in decreased expression of genes
involved in cell adhesionandcytoskeletal organization (Cohenetal, 2019).
Similarly, ncPRC1.1 binds a set of genes that are involved in promoting
leukemogenesis, lack the H3K27me3 mark, and are associated with
transcriptional activity in acute myeloid leukemia stem cells (van den
Boom et al, 2016). Accordingly, the assembly of new ncPRC1 complexes at
SS18-SSX–binding sites in CH310T1/2 cells may drive the expression of a
gene repertoire that sustains SyS development and/or maintenance.
The factors that control the recruitment of SS18-SSX to specific
genomic locations remain to be fully elucidated. Recent studies
have shown that interactions between SS18-SSX and the ncPRC1.1
member KDM2B may account for the recruitment of SS18-SSX to
unmethylated CpG islands (Banito et al, 2018b). However, our study
shows that in addition to these locations, there is widespread
recruitment of SS18-SSX to H3K27me3 enriched regions and distal
regulatory sites devoid of CpG islands, suggesting involvement of
additional mechanisms. Among potential candidates, transcription
factors could provide a natural alternative. A possible scenario that
emerges from our results is that reconfiguration and retargeting of
BAF complexes by SS18-SSX creates broad accessible chromatin
regions in SyS precursor cells, allowing a repertoire of transcription
factors to bind previously inaccessible sites. Binding to such sites
may generate new regulatory elements and gene expression
programs that promote transformation and establishment of SyS
identity. The final outcome may therefore depend on the repertoire
Figure 7. USP7 depletion constitutes an epigenetic vulnerability in synovial sarcoma.
(A) Gene dependency score analysis for a panel of PRC1 members in SyS versus all other cell lines present in the DepMap database identifies USP7 as a selective
vulnerability in SyS. Genes shown in red had an adjusted P-value < 0.05. (B)Heat map showing ChIP-seq signals for USP7 at 4877 SS18-SSX–binding sites in C3H10T1/2 cells.
20-kb windows centered on SS18-SSX–binding sites are shown. (C) Representative example of USP7 recruitment by SS18-SSX at its binding sites in C3H10T1/2 cells. (D, E)
Proximity ligation assay analysis demonstrates direct interaction between USP7 and SS18-SSX in C3H10T1/2 and HSSYII SyS cells. (F) Proximity ligation assay shows a
significant decrease in interactions between the ncPRC1 members RING1B and RYBP following USP7 removal in HSSYII cells. (G) Cell viability assays in SyS (HSSYII, SYO1)
and EwS (A673, RDES) cells upon CRISPR-mediated USP7 KO confirm the selective detrimental effect of USP7 depletion in the SyS cells. *** indicates P-value < 0.0001.
Statistical analyses were performed by t test. See also Fig S8.
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of preexisting developmental transcription factors in cells that
acquire the chromosomal translocation, which may in turn de-
termine permissiveness to the transforming potential of SS18-SSX.
In summary, our results show that the chromatin landscape of
SyS organoids is shaped by chromatin regulation events down-
stream of the SS18-SSX fusion protein. Given that our experiments
reveal these features to be fully reversible, targeting the mecha-
nisms that establish andmaintain oncogenic gene regulation in SyS
is likely to lead to new therapeutic opportunities. For example, the
connection between SS18-SSX and ncPRC1 illustrated by our results
led us to consider the PRC1.1 core member USP7 as a potential
therapeutic target. Accordingly, we find that USP7 down-regulation
leads to the deconstruction of the ncPRC1 complex in SyS cells, and
a marked decrease in their proliferation. SyS organoids can thus
serve as a powerful model to define critical epigenetic mechanisms
driven by SS18-SSX and test their potential therapeutic value.
Materials and Methods
MSCs and tumor organoids
Primary tumor samples andMSCswere collectedwith approval from the
Institutional Review Board of the Center Hospitalier Universitaire Vau-
dois (University of Lausanne). Samples were de-identified before our
analysis. Synovial sarcoma and Ewing sarcoma patient-derived tumor
organoids were cultured in IMDM (Gibco), supplemented with 20% KO
serum (Gibco), 10 ng/ml human recombinant EGF and basic fibroblast
growth factor (Invitrogen), and 1% Pen/Strep (Gibco) in ultra-low at-
tachment flasks (Corning), as previously described (Suva et al, 2009). The
presence and type of the specific translocation was confirmed by RT-
PCR and sequencing of the PCR product. Primary bone marrow-derived
or tissue-derived MSCs were obtained as previously described (Riggi
et al, 2008) and cultured in Iscove’s modified Dulbecco’s medium
containing 10% FCS and 10 ng/ml platelet-derived growth factor BB
(PeProTech). FACS analysis for standard surface markers and karyotype
analysis were performed in each isolated population to confirm cell
identity as normal MSCs.
Cell lines
C3H10T1/2 cell line, Ewing sarcoma cell lines RDES and A673, MET5A
and MRC5 cells were obtained from American Type Culture Col-
lection and were cultured according to American Type Culture
Collection recommendations. HSSY-II cells were purchased from
RIKEN BioResouce Center and SYO1 (RRID:CVCL_7146) were a gift
from Dr A Kawai (Okayama university graduate school of medicine,
dentistry and pharmaceutical sciences, Japan). HSSYII cells bearing
the HA-tagged SS18-SSX1 protein were a gift from Dr Ana Banito
(DFKZ German Cancer Center). All synovial sarcoma cell lines were
cultured in DMEM, 10% FBS, 1% penicillin/streptomycin.
Lentiviral infection, protein expression, and knockdown
Lentiviruses were produced in 293T cells by transfection with gene
delivery vector and packaging vectors GAG/POL and VSV plasmids
using Fugene6 reagent (Promega). Viral supernatants were col-
lected 72 h after transfection and concentrated by centrifugation.
Virus-containing pellets, resuspended in DMEM, were added
dropwise on cells in presence of media supplemented with 8 μg/
ml polybrene. Infected cells were selected with puromycin used
at 1 μg/ml.
Expression of SS18-SSX1-V5 was achieved using the self-
inactivating lentiviral Gene Transfer and Expression system pLIVc
which produces a floxed proviral genome (Cironi et al, 2016).
Knockdown of the transgene (SS18-SSX-V5) was achieved by re-
moving the provirus genome (flanked by two LOXp sites) through
the expression of the CRE recombinase obtained by infection with
the LV-Cre pLKO.1 lentiviral plasmid (25997; Addgene). CRISPR/Cas9
genome editing of cells for the knockout of USP7 was obtained by
infection with the lentiCRISPR v2 plasmid containing the fol-
lowing specific single guide RNA: AGACACCAGTTGGCGCTCCG, TCT-
TCAGCACTGCTTGTGCA (Genscript). The efficiency of each overexpression
or knockdown was de te rmined by Wes te rn b lo t and
qRT-PCR ana l y ses .
Western blot analysis
Western blotting was performed using standard protocols. Primary
antibodies used were mouse anti-V5 (Invitrogen), rabbit anti-USP7
(A300-033A; Bethyl Laboratories), rabbit anti-RING2 (187509;
Abcam), mouse anti-RING2 (sc-101109; Santacruz Biotechnology),
monoclonal anti-HA (Covance Research Product Inc.), mouse anti-
tubulin (Calbiochem), and mouse anti-actin clone AC-40 (Sigma-
Aldrich). Secondary antibodies were goat antirabbit horseradish
peroxidase-conjugated (Dako) and sheep antimouse horseradish
peroxidase-conjugated (Amersham). Membranes were developed
using SuperSignal west pico plus chemioluminescent substrate
(Thermo Fisher Scientific) or WesternBright Sirius Detection Kit
(Advansta). Bands were visualized using the Fusion FX machine
from Vilbert-Loumat. Densitometric analyses were performed using
ImageJ software (https://imagej.nih.gov/ij/).
PLA
PLA was performed using a Duolink II Fluorescence PLA kit (Olink
Bioscience) as instructed by the manufacturer. The cells were
seeded at 70% confluence in 0.2 cm2 dishes, fixed in 4% parafor-
maldehyde in PIPES buffer for 13 min at RT, and permeabilized with
0.3% triton in PBS for 3 min. The following primary antibodies were
used at the specified dilutions: 1: 2,000 for mouse anti-V5 (Invi-
trogen), rabbit anti-V5 (Ab15828; Abcam), and monoclonal anti-HA
(HA.11; Covance); 1:1,000 for rabbit anti RYBP (Ab185971; Abcam),
rabbit anti RING2 (Ab187509; Abcam), rabbit anti EED (Ab4469;
Abcam), and mouse anti EZH2 (H.547.3; Thermo Fisher Scientific);
1:500 for mouse anti RING2 (sc-101109; Santacruz Biotechnology)
and 1:10,000 for goat anti USP7 (PLA0306; Sigma-Aldrich). PLA
amplification was labeled with Alexa Fluor 594 (Olink Bioscience).
Slides were counterstained with DAPI, mounted, and imaged using
the Zeiss Confocal Fluorescent Microscope LSM710, with an oil
immersion objective 63×, NA 1.4. For each channel the pin hole was
set to 0.9 AU. For each sample the Z-stack was acquired with a line
averaging of two passages and with a sampling in the XYZ according
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to the optimal Nyquist criteria. Before analysis, the Z-stack was
converted with maximum intensity projection. The resulting images
were analyzed using ImageJ software (https://imagej.nih.gov/ij/) as
previously described (Cironi et al, 2016). For statistical analysis,
fluorescent foci were counted for each sample in five different
fields each containing an average of 8–10 cells.
Cell growth, viability assays, and EPZ6438 treatment
Global decrease in H3K27m3 was obtained by treating C3H10T1/2
cells for 8 d with 10 μM EPZ6438 (Selleckchem). The drug was
refreshed every second day. At day 8 C3H10T1/2 cells were infected
with V5-tagged SS18-SSX or empty pLIVc vector and harvested 72 h
later to produce total cell lysates and RNA for further analyses. 5–7 d
after infection and puromycin selection, HSSYII, SYO1, A673, and RDES
populations showing a substantial USP7 knockdown were estab-
lished. USP7 knockdown cells or control cells were quantified using
an automated cell counter Countess II (Thermo Fisher Scientific) and
seeded in 60-mm plates at a concentration of 500,000 cells/plate.
Cell count was performed in triplicates at regular intervals over a
period of time of about 10 d. Trypan blue exclusion was used to
evaluate cell viability.
ChIP-seq
ChIP assays were carried out on ~2–5million cells per sample and per
epitope, following the procedures described previously (Mikkelsen et
al, 2007). In brief, chromatin from formaldehyde-fixed cells was
fragmented to a size range of 200–700 bases with a Branson 250
sonifier. Solubilized chromatin was immunoprecipitated with the
indicated antibodies overnight at 4°C. Antibody-chromatin com-
plexes were pulled down with protein G-Dynabeads (Life Technol-
ogies), washed, and then eluted. After cross-link reversal, RNase A,
and proteinase K treatment, immunoprecipitated DNA was extracted
with AMP Pure beads (Beckman Coulter). ChIP DNA was quantified
with Qubit. 1–5 ng ChIP DNA samples were used to prepare se-
quencing libraries, and ChIP DNA and input controls were sequenced
with the Nextseq 500 Illumina genome analyzer.
Antibodies used for these studies were SMARCA2/4 (39805; Active
Motif), H3K4me1 (ab8895; Abcam), H3K4me3 (07-473; Millipore), H3K9ac
(ab4441; Abcam), H3K27ac (39133; Active Motif), H3K27me3 (07-449;
Millipore), H3K36me3 (ab9050; Abcam), V5 (ab15828; Abcam), RING1B
(5694; Cell Signaling), H2AK119ub (8240; Cell Signaling), RYBP (59451204;
Sigma-Aldrich), and USP7 (A300-033A; Bethyl Laboratories).
ChIP-seq data processing and analysis
Alignment of ChIP-seq reads
Reads were aligned to hg19 (human samples) or mm10 (C3H10T1/2
cells) reference genomes using BWA (Li & Durbin, 2009). Aligned
reads were then filtered to exclude PCR duplicates and were ex-
tended to 200 bp to approximate fragment sizes. Density maps were
generated by counting the number of fragments overlapping each
genomic position using igvtools (Thorvaldsdottir et al, 2013), and
normalized to 10 million reads. Average ChIP-seq signals across
genomic intervals were calculated using bwtool (Pohl & Beato, 2014).
ChIP-seq peak calling
We used MACS2 (Zhang et al, 2008) to call peaks using matching
input controls with a q-value threshold of 10−4 for SMARCA2/4 and
RING1B, and 5 × 10−2 for H3K27me3 and using the broad parameter.
Peaks within 200 bp of each other were merged and filtered to
exclude blacklisted regions as defined by the ENCODE consortium
(ENCODE Project Consortium, 2012).
ChIP-seq peak intersections
Consensus peaks in synovial sarcoma organoids were identified
using bedtools (Quinlan&Hall, 2010) and defined as those common
to three out of four samples before merging peaks within 2 kb
(SMARCA2/4) or 5 kb (H3K27me3) using the Bioconductor genomic
ranges package (Lawrence et al, 2013). In C3H10T1/2 cells, SS18-SSX
consensus peaks were defined as those common to both samples
and with at least twofold more ChIP-seq signals in SS18-SSX
samples than in controls.
ChIP-seq peak annotation
Peaks within 1 kb of RefSeq transcription start sites or with strong
H3K4me3 ChIP-seq signals (average normalized signal above eight)
were considered as promoters, peaks overlapping a RefSeq gene
body were considered as distal intragenic and the remaining peaks
were considered distal intergenic. In C3H10T1/2 cells, SS18-SSX
consensus peaks were further annotated using the list of known
CpG in the mm10 genome (http://hgdownload.cse.ucsc.edu/goldenpath/
mm10/database/cpgIslandExt.txt.gz).
Heat maps and composite plots
Signals shown in heat maps (100 bp windows) and composite plots
(10 bp windows) were calculated using bwtool (Pohl & Beato, 2014).
Heat map signals (Figs 2D, 4C and H, 6B and I, and 7B) are in log2
scale, centered on the indicated peaks, and are capped at the 99th
percentile. In Figs 2C and 4E, heat maps show average ChIP-seq
signals at indicated regions. In Fig 4E, SS18-SSX–binding regions
were grouped by hierarchical clustering based on ChIP-seq signals
of histone modifications in control samples. Manual curation was
used to merge clusters into a reduced number of biologically
relevant patterns.
RNA-seq
Total RNA was isolated from cells using NucleoSpin RNA Plus
(Clontech). 0.5–1 μg of total RNA was treated with Ribogold zero to
remove ribosomal RNA. Illumina sequencing libraries were con-
structed using random primers according to the manufacturer’s
instructions using the Truseq Stranded RNA LT Kit.
RNA-seq data processing and analysis
Reads were aligned to hg19 or mm10 reference genomes using STAR
(Dobin et al, 2013). Mapped reads were filtered to exclude PCR
duplicates and reads mapping to known ribosomal RNA coordi-
nates, obtained from rmsk table in the UCSC database (http://
genome.ucsc.edu). Gene expression was calculated using featur-
eCounts (Liao et al, 2014). Only primary alignments with mapping
quality of 10 or more were counted. Counts were transformed to
transcript per million. Signal tracks were generated using bedtools
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(Quinlan & Hall, 2010). Gene and transcript abundances were also
calculated using Cufflinks (Trapnell et al, 2010).
Differential expression analysis
Genes differentially expressed between synovial sarcoma orga-
noids and MSCs (Figs 3A and S3C) were identified using DESeq2
(Love et al, 2014) with at least a fourfold change and an adjusted
P-value < 0.05. For the TCGA sarcoma expression dataset (Cancer
Genome Atlas Research Network. Electronic address edsc, Cancer
Genome Atlas Research Network, 2017), gene expression levels were
obtained by combining all transcripts levels of a given gene. Dif-
ferentially expressed genes between synovial sarcoma and all
other sarcomas (Figs 3D and S3E) and between synovial sarcoma
and all other sarcomas taken individually (Fig S3G) were selected
based on 5-fold and 20-fold changes in average expression, re-
spectively. Differentially expressed genes in C3H10T1/2 cells upon
SS18-SSX lentiviral induction were identified using DESeq2 (Love
et al, 2014), with at least fourfold change and an adjusted P-value <
0.05.
Mapping BAF complex peaks to genes
SMARCA2/4 consensus peaks in synovial organoids were mapped
to all overlapping (for promoter and distal intragenic peaks) or
nearest (for distal intergenic peaks) genes (Fig S3A and B) and
attributed to the category of genes expressed at high or low levels
in synovial sarcoma. Peak width (Figs 3B and E and S3D) and the
percentage of genes associated with narrow or broad peaks (Figs 3C
and F and S3F) were then displayed. Similarly, in Fig S3D, SMARCA2/4
peaks in MSCs were mapped to all overlapping or nearest genes,
attributed to the category of genes expressed at high or low levels
in synovial sarcoma and peak width was then displayed. A similar
mapping was performed for SS18-SSX peaks in mouse C3H10T1/2
cells with genes significantly up- or down-regulated upon SS18-SSX
expression (Fig 5B).
Quantification and statistical analysis
All statistical details of experiments are included in the Figure
legends or the Materials and Methods section.
Data and software availability
The data accompanying this article have been deposited into GEO
under accession number 148724.
Additional resources
To aid our analysis, we also used a publicly available gene expression
dataset from TCGA for a collection of sarcomas available at (https://
toil.xenahubs.net/download/tcga_Kallisto_tpm.gz) (Cancer Genome
Atlas Research Network. Electronic address edsc, Cancer Genome
Atlas Research Network, 2017).
Contact for reagent and resource sharing
Further information and requests for resources and reagents
should be directed to and will be fulfilled by the Lead Contacts Ivan
Stamenkovic (Ivan.Stamenkovic@chuv.ch) and Nicolò Riggi (Nicolo.
Riggi@chuv.ch).
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
202000808.
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